• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting RNA to lower triglycerides: long strides from short molecules.

作者信息

Qamar Arman, Libby Peter, Bhatt Deepak L

机构信息

Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.

出版信息

Eur Heart J. 2019 Sep 1;40(33):2797-2800. doi: 10.1093/eurheartj/ehz321.

DOI:10.1093/eurheartj/ehz321
PMID:31089714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6735893/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c3/6735893/848b030fcd83/ehz321f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c3/6735893/848b030fcd83/ehz321f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c3/6735893/848b030fcd83/ehz321f1.jpg

相似文献

1
Targeting RNA to lower triglycerides: long strides from short molecules.靶向RNA以降低甘油三酯：从小分子迈出的大步进展。
Eur Heart J. 2019 Sep 1;40(33):2797-2800. doi: 10.1093/eurheartj/ehz321.
2
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.武帕努尔森，一种针对 ANGPTL3 mRNA 的 N-乙酰半乳糖胺缀合反义药物，可降低糖尿病、肝脂肪变性和高三酰甘油血症患者的甘油三酯和致动脉粥样硬化脂蛋白。
Eur Heart J. 2020 Oct 21;41(40):3936-3945. doi: 10.1093/eurheartj/ehaa689.
3
Gene therapy: Targeting apoc-III to lower triglycerides.基因疗法：靶向载脂蛋白C-III以降低甘油三酯水平。
Nat Rev Cardiol. 2015 Feb;12(2):64. doi: 10.1038/nrcardio.2014.212. Epub 2014 Dec 23.
4
Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.靶向载脂蛋白 C-III 的锁核酸反义抑制剂能有效且优先地从鼠血浆中的大 VLDL 颗粒中去除甘油三酯。
Eur J Pharmacol. 2014 Jan 15;723:353-9. doi: 10.1016/j.ejphar.2013.11.004. Epub 2013 Nov 20.
5
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3.推进针对RNA的个性化冠心病预防治疗：聚焦血管生成素样蛋白3
Eur Heart J. 2020 Oct 21;41(40):3946-3948. doi: 10.1093/eurheartj/ehaa790.
6
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.小鼠载脂蛋白C-III基因的靶向破坏导致低脂血症并预防餐后高甘油三酯血症。
J Biol Chem. 1994 Sep 23;269(38):23610-6.
7
Lipoproteins and apolipoprotein patterns in rat plasma after liver injury induced by D-galactosamine.D-半乳糖胺诱导肝损伤后大鼠血浆中的脂蛋白和载脂蛋白模式
Hoppe Seylers Z Physiol Chem. 1980 Sep;361(9):1417-25. doi: 10.1515/bchm2.1980.361.2.1417.
8
Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.新型载脂蛋白 C-III 抑制剂治疗心血管疾病高危患者高甘油三酯血症的研究进展。
Expert Opin Pharmacother. 2023 Jun;24(9):1013-1020. doi: 10.1080/14656566.2023.2206015. Epub 2023 Apr 28.
9
Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.载脂蛋白 B 脂蛋白亚类作为类风湿关节炎患者心血管疾病的危险因素。
Arthritis Care Res (Hoboken). 2012 Jul;64(7):993-1000. doi: 10.1002/acr.21646.
10
Targeting ApoC-III to Reduce Coronary Disease Risk.靶向载脂蛋白C-III以降低冠心病风险。
Curr Atheroscler Rep. 2016 Sep;18(9):54. doi: 10.1007/s11883-016-0609-y.

引用本文的文献

1
Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions.靶向载脂蛋白C-III治疗重度高甘油三酯血症：当前研究与未来方向
Cureus. 2024 Aug 17;16(8):e67091. doi: 10.7759/cureus.67091. eCollection 2024 Aug.
2
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.载脂蛋白 C-III：控制甘油三酯代谢的守门员。
Curr Atheroscler Rep. 2023 Mar;25(3):67-76. doi: 10.1007/s11883-023-01080-8. Epub 2023 Jan 23.
3
The dawn of a new era of targeted lipid-lowering therapies.

本文引用的文献

1
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.N-乙酰半乳糖胺修饰的抗载脂蛋白 C3mRNA 反义药物，用于降低甘油三酯和致动脉粥样硬化脂蛋白水平。
Eur Heart J. 2019 Sep 1;40(33):2785-2796. doi: 10.1093/eurheartj/ehz209.
2
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.依折麦布辛伐他汀对全因缺血事件的影响：来自 REDUCE-IT 研究。
J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.
3
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
靶向降脂治疗新时代的曙光。
Eur Heart J. 2022 Sep 7;43(34):3198-3208. doi: 10.1093/eurheartj/ehab841.
4
Lipid Lowering Drugs: Present Status and Future Developments.降脂药物：现状与未来发展。
Curr Atheroscler Rep. 2021 Mar 10;23(5):17. doi: 10.1007/s11883-021-00918-3.
5
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.ω-3 脂肪酸二十碳五烯酸的心血管保护作用的新机制。
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1135-1147. doi: 10.1161/ATVBAHA.119.313286. Epub 2020 Mar 26.
6
Clinical review on triglycerides.关于甘油三酯的临床综述。
Eur Heart J. 2020 Jan 1;41(1):99-109c. doi: 10.1093/eurheartj/ehz785.
载脂蛋白脂蛋白脂酶基因 Triglyceride-Lowering LPL 变异体与 LDL 受体基因 LDL-C-Lowering LDLR 变异体与冠心病风险的相关性研究。
JAMA. 2019 Jan 29;321(4):364-373. doi: 10.1001/jama.2018.20045.
4
Treating Disease at the RNA Level with Oligonucleotides.用寡核苷酸在RNA水平治疗疾病。
N Engl J Med. 2019 Jan 3;380(1):57-70. doi: 10.1056/NEJMra1705346.
5
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.依泽替米贝降低严重高甘油三酯血症患者心血管风险
N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.
6
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.高甘油三酯血症管理中辅助性血脂异常治疗的未满足需求。
J Am Coll Cardiol. 2018 Jul 17;72(3):330-343. doi: 10.1016/j.jacc.2018.04.061. Epub 2018 Jun 20.
7
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.一种人类载脂蛋白C3错义变体和单克隆抗体可加速载脂蛋白C-III清除并降低富含甘油三酯的脂蛋白水平。
Nat Med. 2017 Sep;23(9):1086-1094. doi: 10.1038/nm.4390. Epub 2017 Aug 21.
8
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.REDUCE-IT研究的原理与设计：二十碳五烯酸乙酯干预降低心血管事件试验
Clin Cardiol. 2017 Mar;40(3):138-148. doi: 10.1002/clc.22692. Epub 2017 Mar 15.
9
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南。
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
10
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.抗载脂蛋白 C-III 反义寡核苷酸治疗高甘油三酯血症患者的疗效
N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283.